The Zacks Analyst Blog Highlights Tesla, The Home Depot, Boston Scientific, Frequency Electronics and Bridger Aerospace
Werte in diesem Artikel
For Immediate ReleaseChicago, IL – March 27, 2025 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. TSLA, The Home Depot, Inc. HD, Boston Scientific Corp. BSX, Frequency Electronics, Inc. FEIM and Bridger Aerospace Group Holdings, Inc. BAER.Here are highlights from Wednesday’s Analyst Blog:Top Stock Reports for Tesla, Home Depot & Boston ScientificThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc., The Home Depot, Inc. and Boston Scientific Corp., as well as two micro-cap stocks Frequency Electronics, Inc. and Bridger Aerospace Group Holdings, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Stay Flat a Week Ahead of TariffsToday's Featured Research ReportsTesla’s shares have outperformed the Zacks Automotive - Domestic industry over the past year (+59.7% vs. +14%). The company’s electric vehicle (EV) business is under pressure from pricing challenges and fierce competition, with 2024 marking its first-ever annual delivery decline. CEO Musk’s divided attention and growing political controversies have investors questioning whether Tesla is still his top priority.Further, Tesla expects operating expenses to rise this year, squeezing profitability. Having said that, Tesla's long-term growth prospects remain strong, driven by its thriving Energy Generation & Storage segment, expansive Supercharger network and AI advancements.Tesla’s robust balance sheet, with a high liquidity buffer, supports continued innovation and expansion. Progress in the autonomous vehicle domain, including plans to launch robotaxi services in 2025 bode well. Thus, investors should retain Tesla stock for now.(You can read the full research report on Tesla here >>>)Shares of Home Depot have declined -3.8% over the past year against the Zacks Retail - Home Furnishings industry’s decline of -6.9%. The company’s stocks are driven by a top-line recovery, supported by SRS contributions, stronger-than-expected demand, broad-based category growth, and positive Pro sales.Home Depot delivered better-than-expected sales and EPS in fourth-quarter fiscal 2024, with year-over-year improvements. The company is advancing its "One Home Depot" plan, focusing on supply chain expansion, technology investments, and digital enhancements. The interconnected retail strategy remains a key growth driver, ensuring a seamless shopping experience. HD expects the business momentum from late 2024 to carry into 2025.However, HD continues to see soft engagement for big-ticket discretionary categories, resulting in soft sales. Also, higher interest rates, soft margins and ongoing macroeconomic uncertainties pose risks.(You can read the full research report on Home Depot here >>>)Boston Scientific’s shares have outperformed the Zacks Medical - Products industry over the past year (+48.1% vs. +8.3%). The company is seeing strength across target markets despite macroeconomic concerns and related cost inflation. Strong worldwide demand for its MedSurg and Cardiovascular lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers.The Pain and Brain franchisees are expected to gain solid traction in 2025 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA.The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock. On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds are expected to impact the company’s top line in 2025.(You can read the full research report on Boston Scientific here >>>)Shares of Frequency Electronics have outperformed the Zacks Instruments - Control industry over the past year (+70.1% vs. -2%). This microcap company with market capitalization of $157.24 million has delivered a strong performance, with revenues rising 25.5% to $49.8 million and net income rising to $20.5 million for the nine months ended Jan. 31, 2025, driven by satellite program momentum. Gross margin expanded to 45.4% on improved execution and mix.A $73 million funded backlog (65% convertible in 12 months) supports near-term visibility, reinforced by $23 million in recent contract wins for aerospace and defense applications. Satellite-related revenues now comprise 58% of total sales, reflecting successful penetration into high-growth space markets. FEIM is also investing in quantum sensing aligned with U.S. defense priorities.However, risks include a $1.3 million operating cash outflow, declining cash reserves and a shrinking backlog. Heavy reliance on government contracts and minimal commercial exposure further constrain long-term resilience.(You can read the full research report on Frequency Electronics here >>>)Bridger Aerospace’s shares have underperformed the Zacks Aerospace - Defense industry over the past year (-75.1% vs. -3.7%). This microcap company with market capitalization of $65.06 million is facing risks which include high debt, seasonal revenue concentration, low backlog visibility and rising maintenance costs. International expansion and tech-focused acquisitions offer diversification, though execution risk remains.BAER is currently undervalued relative to its industry peers, with potential for growth if fundamentals continue to improve. Nevertheless, Bridger Aerospace posted record 2024 results, with revenues rising 47.8% to $98.6 million and adjusted EBITDA reaching $37.3 million. The company also achieved a positive operating cash flow of $9.4 million for the first time.Structural shifts toward year-round operations, driven by extended wildfire seasons, are expanding its revenue base. It operates the only U.S. fleet of Super Scoopers in a supply-constrained market, supported by long-term government contracts and new international growth via Spanish Scoopers.(You can read the full research report on Bridger Aerospace here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Zacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report The Home Depot, Inc. (HD): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Frequency Electronics, Inc. (FEIM): Get Free Report Bridger Aerospace Group Holdings, Inc. (BAER): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Boston Scientific und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Boston Scientific
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Tesla
Analysen zu Tesla
Datum | Rating | Analyst | |
---|---|---|---|
28.03.2025 | Tesla Buy | Deutsche Bank AG | |
28.03.2025 | Tesla Outperform | RBC Capital Markets | |
18.03.2025 | Tesla Outperform | RBC Capital Markets | |
12.03.2025 | Tesla Underweight | JP Morgan Chase & Co. | |
11.03.2025 | Tesla Verkaufen | DZ BANK |
Datum | Rating | Analyst | |
---|---|---|---|
28.03.2025 | Tesla Buy | Deutsche Bank AG | |
28.03.2025 | Tesla Outperform | RBC Capital Markets | |
18.03.2025 | Tesla Outperform | RBC Capital Markets | |
28.02.2025 | Tesla Outperform | RBC Capital Markets | |
03.02.2025 | Tesla Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
05.03.2025 | Tesla Neutral | Goldman Sachs Group Inc. | |
03.02.2025 | Tesla Hold | Jefferies & Company Inc. | |
30.01.2025 | Tesla Neutral | Goldman Sachs Group Inc. | |
30.01.2025 | Tesla Hold | Jefferies & Company Inc. | |
02.01.2025 | Tesla Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
12.03.2025 | Tesla Underweight | JP Morgan Chase & Co. | |
11.03.2025 | Tesla Verkaufen | DZ BANK | |
10.03.2025 | Tesla Sell | UBS AG | |
30.01.2025 | Tesla Verkaufen | DZ BANK | |
30.01.2025 | Tesla Underweight | JP Morgan Chase & Co. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Tesla nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen